News | Heart Failure | June 28, 2017

Ohio State Investigating High-Tech Vest for At-Home Heart Failure Management

University one of 40 sites studying SensiVest as possible solution to improve heart failure management, reduce admissions

Ohio State Investigating High-Tech Vest for At-Home Heart Failure Management

June 28, 2017 — Doctors at The Ohio State University Richard M. Ross Heart Hospital are testing a high-tech vest that measures fluid inside the lungs from outside a person’s clothing. It could be a new way to prevent repeated trips to the hospital for the nearly 6 million Americans living with heart failure.

The SensiVest, created by Sensible Medical, uses radar technology that was first used by the military and rescue teams to see through walls and rubble in collapsed buildings.

“Now the technology has been miniaturized and put into a form that allows the radar to go through the chest wall and get an accurate measurement of water inside the lungs,” said William Abraham, M.D., director of the Division of Cardiovascular Medicine at Ohio State Wexner Medical Center. “With heart failure, the heart isn’t strong enough to keep up with the body’s needs and fluid stays in the lungs. Too much fluid makes it hard to breathe.”

Until now, cardiologists have not had a non-invasive way to proactively monitor for fluid changes. The standard has been to rely on patients weighing themselves daily and reporting symptoms such as swelling or shortness of breath. By then, it could be serious enough to require treatment in the hospital.

“We’ve learned these methods don’t catch the disease progression early enough, and that’s why hospitalization and re-hospitalization rates for heart failure have changed very little in the last 20 to 30 years,” Abraham said.

So doctors are testing the vest in a national, randomized clinical trial to see if it effectively monitors and manages lung fluid, reduces hospitalizations and improves quality of life. Abraham leads the trial that includes approximately 40 sites across the country.

All patients enrolled in the trial receive the highest standard of care for heart failure. Those randomized to the treatment group will also use the lung fluid monitor at home to take daily readings. The vest is worn over clothing and a reading takes approximately 90 seconds. The data is uploaded to a secure server where the patient’s cardiologist or nurse can review it.

“We can use that data to see when the lungs are trending towards being too wet and make adjustments to the medication on an outpatient basis or over the phone,” said Rami Kahwash, M.D., director of the Heart and Vascular Research Organization and site leader for the trial at Ohio State. “The goal is to keep the patient within a normal range, feeling well and out of the hospital.”

A previous, small observational study compared hospitalizations before and after using the vest. That study showed an 87 percent reduction in heart failure hospitalizations with vest lung fluid monitoring.

Kenny McIntyre, 59, of Columbus, has been hospitalized twice in the three months since he was diagnosed with heart failure. He recently joined the trial and says the vest is easy to use.

“I’m the type that, unless something hurts me, I don’t want to go to a doctor,” McIntyre said. “I just put the vest on, lay back, hit a button, and let it take my measurements. Every now and then they alter my medications.”

Patients in the trial will be followed for up to nine months.

Watch the VIDEO "Technologies to Reduce Heart Failure Readmissions," an interview with William Abraham at TCT 2016"

Watch the VIDEO "Remote Heart Failure Monitoring Results in Reduced Readmissions — ACC 2015" where Abraham discusses the results of the CHAMPION trial of the CardioMEMS system, another heart failure patient monitoring system.

For more information: www.osumc.edu

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init